|[March 12, 2013]
Medical Aesthetics Veteran Frederick Beddingfield, III, MD, PhD Appointed New Chief Medical Officer of KYTHERA Biopharmaceuticals
LOS ANGELES --(Business Wire)--
Biopharmaceuticals, Inc. (NASDAQ:KYTH), a biotechnology company
focused on the development and commercialization of prescription
products in aesthetic medicine, today announced the appointment of
Frederick Beddingfield, III, MD, PhD as Chief Medical Officer. Dr.
Beddingfield is a board-certified dermatologist who brings exceptional
pharmaceutical and medical device development experience to KYTHERA. He
joins the company from Allergan, Inc., where he worked in an executive
capacity across the entire aesthetics portfolio including Botox® Cosmetic,
Juvederm® and Latisse®. He most recently held the
role of Vice President and Therapeutic Area Head, Dermatology and
Aesthetics. In addition, he has substantial experience across medical
dermatology including acne, rosacea, hair growth and scar prevention.
"Dr. Beddingfield is recognized as one of the leaders in medical
aesthetic innovation and will immediately become an integral member of
KYTHERA's executive team," said Keith Leonard, KYTHERA's President and
CEO. "His depth and breadth of experience will undoubtedly help further
our mission to bring great science, clinical rigor and real innovation
to the growing area of medical aesthetics."
Dr. Beddngfield will lead all clinical research and development,
including strategy, operations, statistics, data management, medical
writing, regulatory and quality.
"KYTHERA's spirit of innovation and their unequaled commitment to
developing safe and novel aesthetic treatments is what attracted me to
the company," said Dr. Beddingfield. "I look forward to building on the
research success of ATX-101 and the opportunity to advance aesthetic
medicine beyond the current treatment categories."
An innovative physician-scientist, Dr. Beddingfield has experience
working on premier products in the aesthetics industry, including
Allergan's Botox Cosmetic, Juvederm and Latisse, all market-leading
aesthetic treatments in their respective categories. During his tenure
at Allergan, Dr. Beddingfield served in several roles, including Chief
Medical Officer, Allergan Medical, and Global Team Leader of several
brands, including Botox Facial Aesthetics, Botox Hyperhidrosis, Dermal
Fillers and Botox Spasticity. Earlier in his career, he held a full-time
faculty position at UCLA David Geffen School of Medicine, Division of
Dermatology, where he continues to maintain an academic appointment as
Assistant Clinical Professor of Medicine. Dr. Beddingfield earned an MD
degree with honors from the University of North Carolina and a PhD in
Policy Analysis from RAND Graduate School of Policy Studies.
Effective March 23, Dr. Beddingfield succeeds Patricia Walker, MD, PhD,
who joined KYTHERA in 2007 as Chief Medical Officer. Prior to joining
KYTHERA, Dr. Beddingfield worked under Dr. Walker's tutelage for three
years at Allergan.
"We are incredibly grateful to Dr. Walker for all of her contributions
in forming the ATX-101 program and helping to build a strong clinical
and regulatory team," said Mr. Leonard. "We are hopeful she will
continue to contribute to KYTHERA's success as a Corporate Advisor."
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization of
novel prescription products for the aesthetic medicine market. KYTHERA's
product candidate, ATX-101, is a potential first-in-class, injectable
treatment currently in Phase III clinical development for the reduction
of submental fat, which commonly presents as an undesirable "double
chin." KYTHERA also maintains an active research interest in hair and
fat biology, pigmentation modulation and facial contouring. Find more
information at http://www.kytherabiopharma.com.
Botox® Cosmetic, Juvederm® and Latisse® are registered trademarks of
[ Back To Technology News's Homepage ]